IkappaB kinase inhibitor (GlaxoSmithKline)

N/A

Report date: 2025/03/20 15:01:08

NME

Base Information

Drug NameIkappaB kinase inhibitor (GlaxoSmithKline)

Drug Alias NameNFkappaB activation inhibitors (GSK)NFkappaB activation inhibitors (SmithKline Beecham)NFkappaB modulators (GSK)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionInhibitor of nuclear factor kappa-B kinase subunit beta inhibitorsInhibitor of nuclear factor kappa-B kinase subunit alpha inhibitorsNuclear factor NF-kappa-B complex modulators

TargetsInhibitor of nuclear factor kappa-B kinase subunit alphaNuclear factor NF-kappa-B complexInhibitor of nuclear factor kappa-B kinase subunit beta

Therapy Area/IndicationsInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsInflammation

Other Information

ATC CodeN/A